{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:19:10Z","timestamp":1780582750658,"version":"3.54.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>The influence of cancer cachexia on the pharmacokinetics of and kidney injury caused by amikacin remains unclear. This study investigated whether the pharmacokinetics of amikacin and the risk of kidney injury are altered with the progression of cancer cachexia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A retrospective analysis was conducted using therapeutic drug monitoring data obtained from 52 cancer patients who received amikacin intravenously for infection(s). The patients were classified into 2 groups based on the status of cachexia using a consensus definition: noncachexia group (n = 31) and cachexia group (n = 21). Differences in amikacin pharmacokinetics and occurrence of kidney injury were compared between the 2 groups. Amikacin pharmacokinetics was calculated based on a 1-compartment model using peak and trough concentrations measured clinically for therapeutic drug monitoring. In addition, intrapatient analysis was conducted based on patients who received amikacin treatments more than once during the study period to examine the alteration in amikacin pharmacokinetics with the progression of cancer cachexia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Systemic clearance of amikacin [median (range)] was significantly (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt; 0.05) lower in the cachexia group [37.3 (11.2\u201387.3) (mL\/min)] than in the noncachexia group [52.0 (19.1\u2013133.4) (mL\/min)]. In contrast, volume of distribution was significantly (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt; 0.05) increased in the cachexia group [0.47 (0.20\u20131.45) L\/kg] compared with the noncachexia group [0.32 (0.21\u20131.00) L\/kg]. There was no difference in the occurrence of kidney injuries between the 2 groups. In an intrapatient analysis of the longitudinal alteration of amikacin pharmacokinetics, an approximately 50% reduction in clearance and 30% increase in volume of distribution were observed as cancer cachexia progressed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The present study suggests that progression of cancer cachexia may reduce amikacin clearance and increase the volume of distribution, but cancer cachexia does not increase amikacin-induced kidney injury.<\/jats:p><\/jats:sec>","DOI":"10.1097\/ftd.0000000000000621","type":"journal-article","created":{"date-parts":[[2019,3,3]],"date-time":"2019-03-03T05:43:55Z","timestamp":1551591835000},"page":"533-537","source":"Crossref","is-referenced-by-count":5,"title":["Amikacin Pharmacokinetics in Terminal Stage of Hematological Malignancy"],"prefix":"10.1097","volume":"41","author":[{"given":"Hirokazu","family":"Nakayama","sequence":"first","affiliation":[{"name":"Pharmacy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Palliative Care, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[{"name":"Hematology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kato","sequence":"additional","affiliation":[{"name":"Pharmacy,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","first-page":"597","article-title":"Aminoglycosides\u201450 years on","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/dkf087","article-title":"Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial","volume":"50","author":"Sanz","year":"2002","journal-title":"J Antimicrob Chemother."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00520-004-0753-8","article-title":"A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia","volume":"13","author":"Rossini","year":"2005","journal-title":"Support Care Cancer"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis."},{"issue":"suppl 1","key":"R5-20230814","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1111\/j.1365-2125.2001.00377.x","article-title":"The therapeutic monitoring of antimicrobial agents","volume":"52","author":"Begg","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute kidney injury in patients with cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N Engl J Med."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1128\/AAC.35.5.944","article-title":"Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy","volume":"35","author":"Davis","year":"1991","journal-title":"Antimicrob Agents Chemother."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijantimicag.2014.09.006","article-title":"First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients","volume":"45","author":"Blackburn","year":"2015","journal-title":"Int J Antimicrob Agents."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cpt1977213362","article-title":"Kinetic model for gentamicin dosing with the use of individual patient parameters","volume":"21","author":"Sawchuk","year":"1977","journal-title":"Clin Pharmacol Ther."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute dialysis quality initiative workgroup. acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/annonc\/mdu086","article-title":"Euro-Impact. validation of the consensus-definition for cancer cachexia and evaluation of a classification model\u2014a study based on data from an international multicentre project (EPCRC-CSA)","volume":"25","author":"Blum","year":"2014","journal-title":"Ann Oncol."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jcph.112","article-title":"Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients","volume":"53","author":"Naito","year":"2013","journal-title":"J Clin Pharmacol."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjc.6600448","article-title":"Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response","volume":"87","author":"Rivory","year":"2002","journal-title":"Br J Cancer."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/dmd.107.018747","article-title":"Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer","volume":"36","author":"Morgan","year":"2008","journal-title":"Drug Metab Dispos."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40262-015-0345-4","article-title":"Pharmacokinetics of morphine, morphine-3-glucuronide and morphine-6-glucuronide in terminally ill adult patients","volume":"55","author":"Franken","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcsm.12012","article-title":"Influence of cancer cachexia on drug liver metabolism and renal elimination in rats","volume":"6","author":"Cvan Trobec","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s00520-003-0486-0","article-title":"Evaluation of nutritional status in advanced metastatic cancer","volume":"11","author":"Sarhill","year":"2003","journal-title":"Support Care Cancer"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1089\/jpm.2015.0548","article-title":"Prevalence and implications of abnormal laboratory results in patients in the terminal phase of life","volume":"19","author":"Masman","year":"2016","journal-title":"J Palliat Med."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1128\/AAC.33.8.1406","article-title":"Pharmacokinetics of amikacin in hematologic malignancies","volume":"33","author":"Kaojarern","year":"1989","journal-title":"Antimicrob Agents Chemother."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/AAC.34.5.702","article-title":"Increased aminoglycoside dosage requirements in hematologic malignancy","volume":"34","author":"Zeitany","year":"1990","journal-title":"Antimicrob Agents Chemother."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clnu.2016.09.004","article-title":"ESPEN guidelines on definitions and terminology of clinical nutrition","volume":"36","author":"Cederholm","year":"2017","journal-title":"Clin Nutr."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2125.2010.03825.x","article-title":"Gentamicin pharmacokinetics in old age and frailty","volume":"71","author":"Hilmer","year":"2011","journal-title":"Br J Clin Pharmacol."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00520-002-0358-z","article-title":"Fluid status of terminally ill cancer patients with intestinal obstruction: an exploratory observational study","volume":"10","author":"Morita","year":"2002","journal-title":"Support Care Cancer"},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00007691-200310000-00012","article-title":"The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity","volume":"25","author":"Kirkpatrick","year":"2003","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201908000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T09:45:42Z","timestamp":1721036742000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201908000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000621","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}